Although evodiamine appreciably increased the hepatic distribution of pravastatin in NASH rats, serum ALT and AST levels, sensitive indicators of liver injury, decreased instead after co-administration of evodiamine and pravastatin, which was likely due to more remarkable therapeutic effects against NASH of combination administration. The gene discussed is GPT; the disease is metabolic dysfunction-associated steatohepatitis.